Chopra Daveen sold $2.9M of EW

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Barclays initiated coverage on 26 medical technology companies, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. The firm sees current valuations as attractive and expects revenue stabilization to boost sentiment. Price targets: SYK at $375, ABT at $120.

The FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.

Edwards Lifesciences (NYSE: EW) received FDA approval for its Autus valve, the first pediatric heart valve designed to expand as a child grows, reducing repeat surgeries. Shares rose to $85.37, giving the company a $49 billion market cap.

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

Edwards Lifesciences (EW) received FDA approval for its AUTUS Size-Adjustable Valve, a pediatric heart valve that expands with the child's growth. The device uses synthetic materials and showed strong clinical results, with 100% success in 62 patients. EW shares rose 1.05% to $86.08.